Health
Asceneuron Secures $100 Million Led by Novo for Alzheimer’s Drug Development
Swiss biotech company Asceneuron has secured $100 million in a Series C funding round led by Novo Holdings, the investment arm of the Novo Nordisk Foundation. This funding will be used to advance the development of ASN51, an oral small-molecule inhibitor of O-GlcNAcase (OGA) aimed at treating Alzheimer's